<DOC>
	<DOCNO>NCT00277264</DOCNO>
	<brief_summary>The objective trial evaluate whether effect one year ( 48 week ) treatment inhaled tiotropium bromide ( Spiriva® - 18 µg daily ) change trough FEV1 , compare placebo patient COPD , affect smoking status .</brief_summary>
	<brief_title>Spiriva® Assessment FEV1 ( SAFE )</brief_title>
	<detailed_description>This multi-centre , randomised , double-blind , placebo-controlled study . The duration subject participation 48 week . There initial screening period 2 week . The first screening visit consist medical history , clinical assessment , safety laboratory assessment complete pulmonary function test . The screening period follow randomised treatment period patient receive tiotropium ( Spiriva ) placebo ratio 2:1 . During treatment period total 5 clinic visit ( include randomisation EOT visit ) . Each visit include lung function measurement clinical assessment ( SQRQ , COPD Symptom score , physician 's global assessment , COPD exacerbations/hospitalisations , vital sign rescue medication use ) addition adverse event reporting . The final visit consist telephone contact 2 week patient complete trial medication . Study Hypothesis : The primary purpose trial evaluate whether effect inhale tiotropium ( Spiriva® ) change trough FEV1 , compare placebo , affect smoking status . The primary endpoint define change trough FEV1 48 week treatment . The primary analysis perform sequential fashion ; firstly , analysis perform patient positive signal see group , analysis perform smoke ex-smoking group separately . Patients define smoker ex-smokers screen visit . Comparison ( ) : Tiotropium ( Spiriva® ) v placebo</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis COPD Stable airway obstruction FEV1 &lt; equal 65 % predict Male female Age &gt; equal 40 year &gt; equal 10 pack year smoke history History exacerbation past year Able train proper use HandiHaler® History asthma Allergic rhinitis atopy Unstable use ( 6 week ) OCS ( &gt; 10 mg daily use ) History life threaten bronchial obstruction , cystic fibrosis bronchiectasis Patients start stop exercise rehabilitation program past twelve month Thoracotomy pulmonary resection lobectomy ( LVRS ) Active tuberculosis Use betablockers Pregnant , nurse woman woman childbearing potential use medically approve mean contraception 6 month less history myocardial infarction Intolerance anticholinergic contain product , and/or lactose component inhalation capsule delivery system History unstable arrhythmia life threaten event change relate therapy past year History cancer , treat basal cell carcinoma , within last 12 month Clinically relevant abnormal baseline haematology , blood chemistry urinalysis Patients narrow angle glaucoma Patients symptomatic benign prostatic hypertrophy Patients bladder neck obstruction Patients plan country 8 week</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>